Detalhe da pesquisa
1.
Preexisting Autoimmunity Is Associated With Increased Severity of Coronavirus Disease 2019: A Retrospective Cohort Study Using Data From the National COVID Cohort Collaborative (N3C).
Clin Infect Dis
; 77(6): 816-826, 2023 09 18.
Artigo
Inglês
| MEDLINE | ID: mdl-37207367
2.
Influence of Prior SARS-CoV-2 Infection on COVID-19 Severity: Evidence from the National COVID Cohort Collaborative.
medRxiv
; 2024 Jan 26.
Artigo
Inglês
| MEDLINE | ID: mdl-38343824
3.
Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19.
Comput Struct Biotechnol J
; 24: 115-125, 2024 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38318198
4.
Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study.
medRxiv
; 2023 Jun 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37398261
5.
Assessing the Effect of Selective Serotonin Reuptake Inhibitors in the Prevention of Post-Acute Sequelae of COVID-19.
medRxiv
; 2023 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36380766
6.
Pre-existing autoimmunity is associated with increased severity of COVID-19: A retrospective cohort study using data from the National COVID Cohort Collaborative (N3C).
medRxiv
; 2023 Feb 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36778264
7.
Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes.
EBioMedicine
; 87: 104413, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36563487
8.
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Diabetes Res Clin Pract
; 194: 110157, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36400170
9.
Metformin is Associated with Reduced COVID-19 Severity in Patients with Prediabetes.
medRxiv
; 2022 Aug 30.
Artigo
Inglês
| MEDLINE | ID: mdl-36093353
10.
Generalizable Long COVID Subtypes: Findings from the NIH N3C and RECOVER Programs.
medRxiv
; 2022 Jul 20.
Artigo
Inglês
| MEDLINE | ID: mdl-35665012
11.
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
J Infect Dis
; 194(12): 1672-6, 2006 Dec 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17109338
12.
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s.
J Infect Dis
; 187(2): 320-5, 2003 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12552459